Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1320099rdf:typepubmed:Citationlld:pubmed
pubmed-article:1320099lifeskim:mentionsumls-concept:C0010823lld:lifeskim
pubmed-article:1320099lifeskim:mentionsumls-concept:C0877837lld:lifeskim
pubmed-article:1320099lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1320099lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:1320099lifeskim:mentionsumls-concept:C0085110lld:lifeskim
pubmed-article:1320099lifeskim:mentionsumls-concept:C0018321lld:lifeskim
pubmed-article:1320099lifeskim:mentionsumls-concept:C0286079lld:lifeskim
pubmed-article:1320099pubmed:issue1lld:pubmed
pubmed-article:1320099pubmed:dateCreated1992-8-5lld:pubmed
pubmed-article:1320099pubmed:abstractTextMice with severe combined immunodeficiency (SCID) inoculated intraperitoneally with murine cytomegalovirus (MCMV) develop a wasting syndrome at 3-4 days and die at 6-9 days after the infection. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine (DHPG, ganciclovir) and (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) were compared for their efficacy against MCMV-induced disease and mortality in SCID mice. Under all treatment conditions, i.e., administration of the test compounds for 5 consecutive days starting on the day of infection (day 0), for 5 consecutive days starting on day 4 after the infection, 2 periods of 3 consecutive days starting on day 0 and day 9 after infection, or as a single dose on day 3 before infection, HPMPC proved far superior to ganciclovir in delaying the onset of the disease and increasing the lifespan of the MCMV-infected mice.lld:pubmed
pubmed-article:1320099pubmed:languageenglld:pubmed
pubmed-article:1320099pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1320099pubmed:citationSubsetIMlld:pubmed
pubmed-article:1320099pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1320099pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1320099pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1320099pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1320099pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1320099pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1320099pubmed:statusMEDLINElld:pubmed
pubmed-article:1320099pubmed:monthMaylld:pubmed
pubmed-article:1320099pubmed:issn0146-6615lld:pubmed
pubmed-article:1320099pubmed:authorpubmed-author:De ClercqEElld:pubmed
pubmed-article:1320099pubmed:authorpubmed-author:BalzariniJJlld:pubmed
pubmed-article:1320099pubmed:authorpubmed-author:NaesensLLlld:pubmed
pubmed-article:1320099pubmed:authorpubmed-author:NeytsJJlld:pubmed
pubmed-article:1320099pubmed:issnTypePrintlld:pubmed
pubmed-article:1320099pubmed:volume37lld:pubmed
pubmed-article:1320099pubmed:ownerNLMlld:pubmed
pubmed-article:1320099pubmed:authorsCompleteYlld:pubmed
pubmed-article:1320099pubmed:pagination67-71lld:pubmed
pubmed-article:1320099pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1320099pubmed:meshHeadingpubmed-meshheading:1320099-...lld:pubmed
pubmed-article:1320099pubmed:meshHeadingpubmed-meshheading:1320099-...lld:pubmed
pubmed-article:1320099pubmed:meshHeadingpubmed-meshheading:1320099-...lld:pubmed
pubmed-article:1320099pubmed:meshHeadingpubmed-meshheading:1320099-...lld:pubmed
pubmed-article:1320099pubmed:meshHeadingpubmed-meshheading:1320099-...lld:pubmed
pubmed-article:1320099pubmed:meshHeadingpubmed-meshheading:1320099-...lld:pubmed
pubmed-article:1320099pubmed:meshHeadingpubmed-meshheading:1320099-...lld:pubmed
pubmed-article:1320099pubmed:meshHeadingpubmed-meshheading:1320099-...lld:pubmed
pubmed-article:1320099pubmed:meshHeadingpubmed-meshheading:1320099-...lld:pubmed
pubmed-article:1320099pubmed:meshHeadingpubmed-meshheading:1320099-...lld:pubmed
pubmed-article:1320099pubmed:meshHeadingpubmed-meshheading:1320099-...lld:pubmed
pubmed-article:1320099pubmed:meshHeadingpubmed-meshheading:1320099-...lld:pubmed
pubmed-article:1320099pubmed:meshHeadingpubmed-meshheading:1320099-...lld:pubmed
pubmed-article:1320099pubmed:meshHeadingpubmed-meshheading:1320099-...lld:pubmed
pubmed-article:1320099pubmed:year1992lld:pubmed
pubmed-article:1320099pubmed:articleTitleEfficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice.lld:pubmed
pubmed-article:1320099pubmed:affiliationRega Institute for Medical Research, Leuven, Belgium.lld:pubmed
pubmed-article:1320099pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1320099pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1320099lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1320099lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1320099lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1320099lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1320099lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1320099lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1320099lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1320099lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1320099lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1320099lld:pubmed